Psychological Assessment of Patients With Biotin-Thiamine-Responsive Basal Ganglia Disease

Overview

Journal Child Neurol Open

Specialty Neurology

Date 2017 Sep 26

PMID 28944253

Citations 4

Authors

Majid Alfadhel

Amal Al-Bluwi

Affiliations

Soon will be listed here.

Abstract

Biotin-thiamine-responsive basal ganglia disease is a devastating autosomal recessive inherited neurological disorder. We conducted a retrospective chart review of all patients with biotin-thiamine-responsive basal ganglia disease who underwent a formal psychological assessment. Six females and 3 males were included. Five patients (56%) had an average IQ, two patients (22%) had mild delay, and two (22%) had severe delay. A normal outcome was directly related to the time of diagnosis and initiation of treatment. Early diagnosis and immediate commencement of treatment were associated with a favorable outcome and vice versa. The most affected domain was visual motor integration, while understanding and mathematical problem-solving were the least affected. In summary, this is the first study discussing the psychological assessment of patients with biotin-thiamine-responsive basal ganglia disease. The results of this study alert clinicians to consider prompt initiation of biotin and thiamine in any patient presenting with neuroregression and a basal ganglia lesion on a brain magnetic resonance imaging.

Citing Articles

Developing of Biotin-Thiamine Responsive Basal Ganglia Disease after Accidental Ingestion of Ethyl Alcohol: A Case Report.

Aldosari A, Arisha A, Ibrahim A, Gongi M J Epilepsy Res. 2024; 13(2):59-62.

PMID: 38223361 PMC: 10783965. DOI: 10.14581/jer.23010.

Biotin-Thiamine-Responsive Basal Ganglia Disease in Children: A Treatable Neurometabolic Disorder.

Saini A, Sharma S Ann Indian Acad Neurol. 2021; 24(2):173-177.

PMID: 34220059 PMC: 8232498. DOI: 10.4103/aian.AIAN_952_20.

[Paroxysmal crying and motor regression for more than two months in an infant].

Wen Y, Wang J, Chen Y, Bao X Zhongguo Dang Dai Er Ke Za Zhi. 2019; 21(4):399-404.

PMID: 31014436 PMC: 7389214.

Biotin-Thiamine-Responsive Basal Ganglia Disease: Case Report and Follow-Up of a Patient With Poor Compliance.

Alabdulqader M, Al Hajjaj S Child Neurol Open. 2018; 5:2329048X18773218.

PMID: 29770345 PMC: 5946631. DOI: 10.1177/2329048X18773218.

References

Tabarki B, Alfadhel M, Alshahwan S, Hundallah K, Alshafi S, AlHashem A . Treatment of biotin-responsive basal ganglia disease: Open comparative study between the combination of biotin plus thiamine versus thiamine alone. Eur J Paediatr Neurol. 2015; 19(5):547-52. DOI: 10.1016/j.ejpn.2015.05.008. View

Alfadhel M, Almuntashri M, Jadah R, Bashiri F, Al Rifai M, Al Shalaan H . Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis. 2013; 8:83. PMC: 3691666. DOI: 10.1186/1750-1172-8-83. View

Ortigoza-Escobar J, Molero-Luis M, Arias A, Oyarzabal A, Darin N, Serrano M . Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome. Brain. 2015; 139(Pt 1):31-8. DOI: 10.1093/brain/awv342. View

Gerards M, Kamps R, van Oevelen J, Boesten I, Jongen E, de Koning B . Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome. Brain. 2013; 136(Pt 3):882-90. DOI: 10.1093/brain/awt013. View

Ozand P, Gascon G, Al Essa M, Joshi S, Al Jishi E, Bakheet S . Biotin-responsive basal ganglia disease: a novel entity. Brain. 1998; 121 ( Pt 7):1267-79. DOI: 10.1093/brain/121.7.1267. View

Sremba L, Chang R, Elbalalesy N, Cambray-Forker E, Abdenur J . Whole exome sequencing reveals compound heterozygous mutations in causing biotin-thiamine responsive basal ganglia disease. Mol Genet Metab Rep. 2016; 1:368-372. PMC: 5121344. DOI: 10.1016/j.ymgmr.2014.07.008. View

Schanzer A, Doring B, Ondrouschek M, Goos S, Garvalov B, Geyer J . Stress-induced upregulation of SLC19A3 is impaired in biotin-thiamine-responsive basal ganglia disease. Brain Pathol. 2013; 24(3):270-9. PMC: 8029177. DOI: 10.1111/bpa.12117. View

Tabarki B, Al-Shafi S, Al-Shahwan S, Azmat Z, Al-Hashem A, Al-Adwani N . Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology. 2012; 80(3):261-7. DOI: 10.1212/WNL.0b013e31827deb4c. View

Kevelam S, Bugiani M, Salomons G, Feigenbaum A, Blaser S, Prasad C . Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy. Brain. 2013; 136(Pt 5):1534-43. DOI: 10.1093/brain/awt054. View

10.

Pronicka E, Piekutowska-Abramczuk D, Ciara E, Trubicka J, Rokicki D, Karkucinska-Wieckowska A . New perspective in diagnostics of mitochondrial disorders: two years' experience with whole-exome sequencing at a national paediatric centre. J Transl Med. 2016; 14(1):174. PMC: 4903158. DOI: 10.1186/s12967-016-0930-9. View

11.

Zeng W, Al-Yamani E, Acierno Jr J, Slaugenhaupt S, Gillis T, MacDonald M . Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet. 2005; 77(1):16-26. PMC: 1226189. DOI: 10.1086/431216. View